Clinical trial
Lantus in Prediabetes
NCT00348972 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00348972 |
|---|---|
| Title | Lantus in Prediabetes |
| Official title | Assessment of Safety and Tolerability of Lantus® (Insulin Glargine) in Subjects With Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hyperglycemia, Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Lantus® (insulin glargine) |
| Enrollment | 20 |
| Start date | Feb 1, 2002 |
| First posted | Jul 6, 2006 |
| Last update posted | Jul 6, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: